HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives.

Abstract
The in-vivo anti-influenza-virus activity of Stachyflin derivatives (III and its phosphate ester, III-Phos), a new class of haemagglutinin fusion inhibitor, and the improvement of their absorption after oral or intranasal administration were studied in mice, rats, and ferrets. The absorption of III in PEG 4000 and III-Phos aqueous solution increased about three and four fold in AUC after oral administration to uninfected mice compared with that of 0.5% HPMC (hydroxypropyl-methylcellulose) suspension. Using a mouse influenza virus infection model, significant anti-influenza-virus activity was observed in infected mice treated orally with these compounds dissolved in PEG 4000 or distilled water, respectively, but not in mice treated with 0.5% HPMC. The in-vivo anti-influenza-virus activity in ferrets, a good model for influenza virus infection in man, was also studied. Although the concentration of III in plasma was above the IC50 against the influenza virus strain used for 6h after the oral administration of III in PEG 400 to uninfected ferrets, no in-vivo anti-influenza-virus activity was observed at the same dosage given 4 times daily for 3 days. The intranasal administration of III-Phos, which was expected to have a more notable in-vivo anti-influenza-virus activity, was examined. III-Phos, whose intranasal absorption had been improved by the modification of III with phosphate ester in rats, inhibited viral replication in the nasal cavity and suppressed influenza-virus-induced fever when administered intranasally to infected ferrets. This study demonstrates that intranasally administered compounds with anti-influenza-virus activity must permeate the nasal membranes to produce their anti-influenza-virus effect.
AuthorsJ Yoshimoto, S Yagi, J Ono, K Sugita, N Hattori, T Fujioka, T Fujiwara, H Sugimoto, N Hashimoto
JournalThe Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 52 Issue 10 Pg. 1247-55 (Oct 2000) ISSN: 0022-3573 [Print] England
PMID11092569 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • Sesquiterpenes
  • stachyflin
  • stachyflin III
  • stachyflin III, phosphate ester
Topics
  • Absorption
  • Animals
  • Antiviral Agents (blood, chemistry, pharmacokinetics)
  • Drug Evaluation, Preclinical
  • Ferrets
  • Humans
  • Influenza A virus (drug effects, metabolism)
  • Influenza, Human (drug therapy, metabolism)
  • Intestine, Small (metabolism)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Nasal Cavity (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Sesquiterpenes (blood, chemistry, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: